Company Overview
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.30.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -11.84% |
| 6 Months: | -17.79% |
| 3 Months: | +22.94% |
| 1 Month: | +12.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 25.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PMVP PMV Pharmaceuticals, Inc. PHARMA | 1.34 | -0.94 | $71.63M | 0.00% | -81.99% | -70.93% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.56M | 22.88M | 22.52M | 19.24M | 19.02M |
| Operating Income | - | - | -6.44M | -7.65M | -8.09M | -8.70M | -11.67M | -13.05M | -15.10M | -18.62M | -17.89M | -19.38M | -21.48M | -20.12M | -19.63M | -18.22M | -20.17M | -21.89M | -21.56M | -22.88M | -22.52M | -19.24M | -19.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.53M | -22.85M | -22.49M | -19.21M | -18.98M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.63M | -21.20M | -21.07M | -18.01M | -18.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.20M | 5.00K | -6.00K | 26.00K | 0 |
| Net Income | -6.00M | -6.13M | -6.17M | -7.25M | -7.97M | -8.76M | -11.60M | -12.87M | -15.01M | -18.43M | -17.31M | -18.23M | -19.13M | -17.44M | -16.64M | -15.27M | -1.21M | -19.23M | -17.44M | -21.21M | -21.06M | -18.04M | -18.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.33 | -0.41 | -0.38 | -0.40 | -0.42 | -0.38 | -0.34 | -0.30 | -0.02 | -0.37 | -0.34 | -0.41 | -0.40 | - | -0.34 |
| R&D Expense | - | - | 4.89M | 5.96M | 5.80M | 5.99M | 7.50M | 7.66M | 9.16M | 11.84M | 11.46M | 13.67M | 15.07M | 13.84M | 13.59M | 13.19M | 14.63M | 16.95M | 17.44M | 18.40M | 18.21M | - | 15.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 77.04M | 80.13M | 85.45M | 86.21M |
| Operating Income | -18.89M | -26.64M | -34.94M | -58.29M | -77.04M | -80.13M | -85.45M | -86.21M |
| EBITDA | - | - | - | - | -76.72M | -78.88M | -84.30M | -86.07M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -73.33M | -68.96M | -74.81M | -79.91M |
| Tax Provision | - | - | - | - | -9.00K | 2.00K | -16.10M | -2.17M |
| Net Income | -17.54M | -25.35M | -34.44M | -57.85M | -73.32M | -68.96M | -58.71M | -77.74M |
| Diluted EPS | - | - | -2.40 | -1.28 | -1.61 | -1.44 | -1.14 | -1.48 |
| R&D Expense | 13.85M | 20.76M | 23.93M | 36.49M | 51.99M | 55.88M | 58.53M | 69.88M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 103.03M | 365.53M | - | 270.31M | 252.15M | 191.29M | 116.56M |
| Current Assets | - | - | - | - | - | 247.01M | 207.41M | 175.66M | 115.23M |
| Cash & Equivalents | - | - | 73.28M | 361.42M | - | 108.30M | 37.71M | 40.88M | 37.98M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 4.57M | 6.41M | - | 24.28M | 26.46M | 15.21M | 11.85M |
| Current Liabilities | - | - | 4.52M | 6.41M | - | 10.83M | 14.03M | 14.37M | 11.41M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 13.98M | 13.29M | 1.19M | 838.00K |
| Total Equity | -29.73M | -46.14M | -70.47M | 359.12M | - | 246.03M | 225.69M | 176.08M | 104.71M |
| Shares Outstanding | - | - | - | - | - | 45.77M | 51.45M | 51.94M | 53.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.18M | -22.07M | -32.74M | - | -63.76M | -55.66M | -51.28M | -73.58M |
| Investing Cash Flow | 21.69M | 3.23M | 27.91M | - | -1.37M | -50.55M | 53.35M | 70.17M |
| Financing Cash Flow | - | 61.80M | 292.97M | - | 958.00K | 35.58M | 313.00K | 505.00K |
| Capital Expenditure | -452.00K | -109.00K | -148.00K | - | -7.98M | -962.00K | -655.00K | -29.00K |
| Free Cash Flow | -15.63M | -22.17M | -32.89M | - | -71.74M | -56.62M | -51.94M | -73.61M |
| Net Change in Cash | - | - | - | - | -64.17M | -70.62M | 2.38M | -2.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 38.0% | 36.0% | -9.6% | - | -29.8% | -30.6% | -33.3% | -74.2% |
| ROCE % | - | -27.0% | -9.7% | - | -29.7% | -33.7% | -48.3% | -82.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 9.97% | 5.33M | $8.00M |
| 2 | Tang Capital Management, LLC | 7.94% | 4.25M | $6.37M |
| 3 | Sio Capital Management, LLC | 4.93% | 2.63M | $3.95M |
| 4 | Euclidean Capital Llc | 4.92% | 2.63M | $3.94M |
| 5 | Adage Capital Partners GP L.L.C. | 4.41% | 2.36M | $3.54M |
| 6 | Acadian Asset Management. LLC | 4.15% | 2.22M | $3.32M |
| 7 | Vanguard Capital Management LLC | 3.76% | 2.01M | $3.02M |
| 8 | ArrowMark Colorado Holdings LLC | 3.67% | 1.96M | $2.94M |
| 9 | Two Sigma Investments, LP | 3.66% | 1.95M | $2.93M |
| 10 | Eversept Partners, LP | 3.54% | 1.89M | $2.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PMVP
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPOWprcm5KLVoyMFdmWlRsRmdpVG1aX1JOTUEyVG9xekVVSVJhNTZ5ME1UUVB6ZnlSTzZSRmZ3SU1DU2syRlhPQXlRVG1xRnZaR0RqZ2pYd3hBT29PRXN0bGk1M1BuSVBEZ0IzZ2VDY1lUakJtQ1RRWkY4a0tKbFJQMFEyakRqVnNFLUF0V1…
Ovarian cancer drug trial completes enrollment; PMV plans 2027 filing - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNRzl2Nm5fN0dZTXRZNkNxNGp6MWdhakEtbFVhYjFlSWdzU1UxWjR0dVJ1UHFOSzF0MUNQVmtQQlJsQThnYS1OWlh0QUg2YWhER01oY2cxSFo0TjlkODFVVWotMTdyRm45dV9MTk5RemcwcllRSUZQMC1hOUFzY1FuQTFTYW82TVE1RWRTR1…
PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRVBSQkxFZkliS2xiY1Z4UFNnMjhBTlRKWERvTG51UmVKQWdJak9Jbm0xV3RPRE9DeGIyWXRlR1A0OHFsdkdUdUtwVEpGRDhKYUJkSzFoMl9QWEdTelUtVmFVbi1kMTdTems3UDVVblE0Uy1SdHh1Ui1kS2JiUUJvOV9UTVBDM2pfRjk5Zj…
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9weU5ZQmFydVZfeFVUM25IeVc3N3BxREJROEZYMUFEcFdBRmI1ZmhLb2htd2pHLUVuOE96bzVpcmtjWEJHaVE3TTEzc1J4T1o3?oc=5" target="_blank">Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP St…
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxOb3BfejljcFM3SUNVRkdqbEdNa1VIRXBnT1NqREtPUFVyVGRzc1hYM1lGaW5BbVphZDhBeEFYZlNaT1BxdzJBZ0Z4WjEtNFVRVUdFRzJNYzU4WE5JRkh4SzA2cS05eHBPcURUa1BvQU9YbUkycGJCZ05VYWpWQW5RZWdnZDR2dVhDTFlXR1…
PMVP - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5GU043bWEwUlJjLUd1YUdUZy15aHBXSjlQeEN4UjBRLXhxSVhncFh4bFp6TWJLWFdjRFNFS1dUUVdHZV9rQnc?oc=5" target="_blank">PMVP</a> <font color="#6f6f6f">Finviz</font>…
PMVP — Frequently Asked Questions
What is the current share price of PMV Pharmaceuticals, Inc. (PMVP)?
As of 2026-09-19 21:16 PDT, PMV Pharmaceuticals, Inc. (PMVP) trades at $1.34 on NasdaqGS. Its 52-week range is $1.02 to $1.80.
What is the market capitalisation of PMVP?
PMV Pharmaceuticals, Inc. (PMVP) has a market capitalisation of $71.63M on NasdaqGS.
What is the P/E ratio of PMVP?
PMVP trades at a trailing price-to-earnings (P/E) ratio of -0.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.12.
What is the return on equity (ROE) of PMVP?
PMVP has a return on equity (ROE) of -70.93%. Its return on capital employed (ROCE) is -81.99%.
Is PMVP a good stock to buy?
This page provides a data-driven analysis of PMV Pharmaceuticals, Inc. (PMVP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.